Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study describes a successful reconstructive A-T flap surgery on a 74-year-old male with a 35mm basal cell carcinoma on the scalp, resulting in a 50mm defect, with no complications and optimal functional and cosmetic outcomes reported.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

Dermoscopy helps diagnose frontal fibrosing alopecia by identifying specific scalp features.

Frontal fibrosing alopecia may be caused by an autoimmune reaction and hormonal imbalance.

This discussion highlights that alopecia areata incognita is challenging to diagnose and treat, with systemic corticosteroids potentially leading to remission when local treatments fail.

This study found that females with frontal fibrosing alopecia had more preauricular lines than age-matched controls, indicating a potential new clinical marker for the condition.

This study found that the presence of CD3(+) T-cells within empty follicular fibrous tracts is a reliable indicator for diagnosing diffuse alopecia areata instead of pattern hair loss.

This study found that eyelash loss, facial papules, and body hair involvement were linked to severe frontal fibrosing alopecia, and antiandrogens were the most effective treatment.

This case report describes a 50-year-old woman with frontal fibrosing alopecia who showed no improvement despite multiple treatments, including intralesional triamcinolone and topical glucocorticoids.

This chapter reviews trichoscopic-pathologic correlations in Frontal Fibrosing Alopecia and reports no new clinical results; the authors discuss genetics, clinical patterns, and unusual variants associated with this condition.

This article discusses the DOAJ, a comprehensive index of international open access journals, and emphasizes its role in providing free quality content online without presenting new research findings.

This hypothesis article explores frontal fibrosing alopecia as a potential autoimmune condition and calls for future research to investigate this possibility, but reports no new clinical results.

Abatacept may help some people with alopecia areata regrow hair.

This study found that limb hair loss in frontal fibrosing alopecia is inflammatory and permanent, but lacks the classic scarring features seen in scalp alopecia, prompting potential misdiagnosis as alopecia areata.

This research presents the Dodatek A model, elaborating on androgen function through new mathematical indices and methodological improvements, shifting focus from serum hormone concentrations to system interactions to better describe androgen activity comprehensively.

This study found that tofacitinib was a safe and effective treatment for patients with moderate-to-severe alopecia areata, with a significant percentage achieving notable reductions in their Severity of Alopecia Tool scores after 18 months.

In this study, tofacitinib treatment led to significant hair regrowth in 60% of patients with moderate-to-severe alopecia areata, suggesting potential for JAK inhibitors in treating this condition.

This review discusses fibrosing alopecia in a pattern distribution and highlights diagnostic features, but reports no new clinical results; the authors emphasize the value of trichoscopy and histology in diagnosis.

This review discusses the potential link between contact allergy and frontal fibrosing alopecia, noting the presence of implicated allergens in current literature, but reports no new clinical findings.

This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.

In this study, Dodatek A operationalizes the Functional Androgen Axis framework by defining three system-level indices and an efficiency metric to describe androgen function, incorporating key methodological improvements and acknowledging significant limitations for future empirical validation.

This article discusses congenital atrichia and presents no new clinical findings.

This study demonstrated that the Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata cases with high sensitivity and specificity in a dermatology clinic setting.

This study found that blocking LFA-1 signaling completely prevented the development of alopecia areata in C3H/HeJ mice, suggesting that LFA-1 plays a crucial role in the disease's pathogenesis and could be a target for new therapies.

Fibrosing alopecia in a pattern distribution is a unique hair loss condition with inflammation and scarring, resembling but distinct from common balding.

This study observed that oral tofacitinib was reasonably well-tolerated but had limited efficacy in treating alopecia areata, with a clinical response seen in 41.4% of patients over six months.

This study found that Latina girls with a unique form of alopecia areata had small, confetti-like hair loss macules that resolved spontaneously within months, suggesting a distinct variant from classic alopecia areata.

This study found that Finasteride significantly reduced the proliferation of acute myeloid leukemia cell lines by inhibiting androgen receptor activity.